2 - TI Pharma

Chapter 2 Glucocorticoids: metabolic side effects
131. Sutinen j, Kannisto K, Korsheninnikova E, Nyman T, Ehrenborg E, Andrew R, Wake Dj, Hamsten A,
Walker BR, Yki-jarvinen H. In the lipodystrophy associated with highly active antiretroviral therapy,
pseudo-Cushing’s syndrome is associated with increased regeneration of cortisol by 11betahydroxysteroid
dehydrogenase type 1 in adipose tissue. Diabetologia. 2004;47(10):1668-71.
132. Draper N, Walker EA, Bujalska Ij, Tomlinson jW, Chalder SM, Arlt W, Lavery GG, Bedendo O,
Ray DW, Laing I, Malunowicz E, White PC, Hewison M, Mason Pj, Connell jM, Shackleton CH,
Stewart PM. Mutations in the genes encoding 11beta-hydroxysteroid dehydrogenase type 1 and
hexose-6-phosphate dehydrogenase interact to cause cortisone reductase deficiency. Nat Genet
2003;34(4):434-9.
133. Schacke H, Berger M, Rehwinkel H, Asadullah K. Selective glucocorticoid receptor agonists (SEGRAs):
novel ligands with an improved therapeutic index. Mol Cell Endocrinol. 2007;275(1-2):109-17.
134. Barf T, Vallgarda j, Emond R, Haggstrom C, Kurz G, Nygren A et al. Arylsulfonamidothiazoles as a
new class of potential antidiabetic drugs. Discovery of potent and selective inhibitors of the 11betahydroxysteroid
dehydrogenase type 1. j Med Chem. 2002;45(18):3813-5.
135. Coppola GM, Kukkola Pj, Stanton jL, Neubert AD, Marcopulos N, Bilci NA, Wang H, Tomaselli HC,
Tan j, Aicher TD, Knorr DC, jeng AY, Dardik B, Chatelain RE. Perhydroquinolylbenzamides as novel
inhibitors of 11beta-hydroxysteroid dehydrogenase type 1. j Med Chem. 2005;48(21):6696-712.
136. Alberts P, Nilsson C, Selen G, Engblom LO, Edling NH, Norling S, Klingstrom G, Larsson C, Forsgren
M, Ashkzari M, Nilsson CE, Fiedler M, Bergqvist E, Ohman B, Bjorkstrand E, Abrahmsen LB. Selective
inhibition of 11 beta-hydroxysteroid dehydrogenase type 1 improves hepatic insulin sensitivity in
hyperglycemic mice strains. Endocrinology. 2003;144(11):4755-62.
137. julian LD, Wang Z, Bostick T, Caille S, Choi R, DeGraffenreid M, Di Y, He X, Hungate RW, jaen jC, liu
j, Monshouwer M, McMinn D, Rew Y, Sudom A, Sun D, Tu H, Ursu S, Walker N, Yan X, Ye Q, Powers
jP. Discovery of novel, potent benzamide inhibitors of 11beta-hydroxysteroid dehydrogenase
type 1 (11beta-HSD1) exhibiting oral activity in an enzyme inhibition ex vivo model. j Med Chem.
2008;51(13):3953-60.
138. johansson L, Fotsch C, Bartberger MD, Castro VM, Chen M, Emery M, Gustafsson S, Hale C, Hickman
D, Homan E, jordan SR, Komorowski R, Li A, McRae K, Moniz G, Matsumoto G, Orihuela C, Palm G,
Veniant M, Wang M, Williams M, Zhang j. 2-amino-1,3-thiazol-4(5H)-ones as potent and selective
11beta-hydroxysteroid dehydrogenase type 1 inhibitors: enzyme-ligand co-crystal structure and
demonstration of pharmacodynamic effects in C57Bl/6 mice. j Med Chem. 2008;51(10):2933-43.
139. Saltiel AR, Kahn CR. Insulin signalling and the regulation of glucose and lipid metabolism. Nature.
2001;414(6865):799-806.
50